Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial
Recruiting
Phase 4
Interventional Study
Laryngoscopic Stress Response
Dexmedetomidine
Lignocaine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 70 (estimated)
- Sponsor
- Rawalpindi Institute of Cardiology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
American Society of Anesthesiologists (ASA) physical status III-IV. Patients who are at risk of cardiovascular events
Exclusion Criteria:
1. Patients with known hypersensitivity to dexmedetomidine and Lignocaine.
2. Patients on medications that could interfere with the study (…
Contacts